BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Aussie Stem Cell Company Cynata Therapeutics Signs LOI with apceth GmbH
Global Cooperation Australia’s Cynata Therapeutics to Partner with Germany’s apceth GmbH & Co. KG

Aussie Stem Cell Company Cynata Therapeutics Signs LOI with apceth GmbH

December 17, 2015 By Cade Hildreth (CEO) Leave a Comment

Global Cooperation: Australia’s Cynata Therapeutics to Partner with Germany’s apceth GmbH & Co. KGCynata Therapeutics, an Australian stem cell company with a powerful mesenchymal stem cell (MSC) manufacturing technology, has signed a Letter of Intent (LOI) with the German giant,apceth GmbH & Co. a company developing genetically engineered, next generation mesenchymal stem cell (MSC) therapeutics.

Discover class-defining bioproduction tools.

This is a significant announcement, because apceth GmbH & Co. KG is an extremely well-funded group. Their major shareholders are the Strungmann family, which previously owned Hexal, one of the largest manufacturers of generic pharmaceuticals in Europe. While apceth GmbH & Co. KG is not widely known within the United States, it is a major force within the European Union (EU) biotech market. 

Furthermore, the announcement is the second of its kind for Cynata in the past two weeks, suggesting favorable momentum for the stem cell company. The other Letter of Intent (LOI) was signed with Regience K.K. in Japan, on December 3, 2015.

As stated in the press release issued by Cynata Therapeutics:

“Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has signed a Letter of Intent (LOI) regarding a future option and license agreement with apceth GmbH & Co. KG, a leading company using modified MSCs to treat cancer and other life-altering conditions.

Rooster DevServices

The LOI lays the path for a commercial transaction between Cynata and apceth pursuant to which, Cynata would grant to apceth certain rights, to develop and commercialise Cynata’s proprietary CymerusTM therapeutic mesenchymal stem cell (MSC) technology. During the coming weeks, under the LOI, the management teams of apceth and Cynata will evaluate and define the key terms of an option and license agreement.”

To learn more, view the full press release here.

Rate this post

Filed Under: MSCs, Stem Cells Tagged With: apceth GmbH, cynata therapeutics, mesenchymal stem cells, stem cell, stem cell therapy

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.